Zentek (ZTEK)
NASDAQ:ZTEK
ZTEK Stock Chart & Stats
$0.69
-$0.05(-4.63%)
At close: 4:00 PM EST
$0.69
-$0.05(-4.63%)
Day’s Range― - ―
52-Week Range$0.50 - $1.84
Previous CloseN/A
Volume66.53K
Average Volume (3M)63.87K
Market Cap
$57.28M
Enterprise Value$79.68M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$1.90M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding107,543,560
10 Day Avg. Volume35,879
30 Day Avg. Volume63,873
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)11.24
Price to Sales (P/S)190.02
P/FCF Ratio-26.38
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue84.51
Enterprise Value/Gross Profit-113.01
Enterprise Value/Ebitda-10.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetModest leverage and low debt provide balance-sheet flexibility, lowering short-term insolvency risk and enabling the company to fund R&D, pilot manufacturing, or small partnerships without immediate refinancing. This cushion supports execution over the next several months.
Strong Revenue Growth TrendVery strong reported revenue growth (1358% YoY) indicates early traction from R&D to sales despite the small base. If sustained, this top-line momentum can validate product-market fit and attract partners or licensing deals, underpinning longer-term commercialization prospects.
IP-centric Graphene/nanotech FocusZentek's focus on graphene and nanotech plus an IP-centric model (R&D, IP development, manufacturing/licensing/partnership options) creates optionality. Multiple commercialization pathways reduce single-point execution risk and preserve strategic flexibility to monetize technology over time.
Bears Say
Ongoing Cash BurnConsistent negative operating and free cash flow means the company must rely on external funding to maintain operations and scale. Persistent cash burn increases dilution risk, constrains marketing/manufacturing investments, and can delay commercialization milestones.
Very Small Revenue BaseTTM revenue of only ~$0.94M signals very limited commercial scale. Small revenue constrains ability to absorb fixed costs, negotiate favorable supplier or partner terms, and makes profitability more sensitive to single contracts, extending the timeline to self-sufficiency.
Deep Negative Profitability & MarginsDeep operating losses and a negative TTM gross margin indicate current product economics are unprofitable. Structural negative margins require fundamental changes—cost reduction, pricing changes, or different product mix—to reach sustainable profitability, which is uncertain near-term.
Zentek News
ZTEK FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.50 and its highest was $1.84 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $57.28M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Jul 01, 2026 which is in 90 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Feb 17, 2026. The company reported -$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.017.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 107,543,560 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.674%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 3.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth C$70.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.65%
12-Months-Change
Fundamentals
Return on Equity
-61.26%
Trailing 12-Months
Asset Growth
-4.13%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―
Ownership Overview
4.01% Insiders
0.05% Mutual Funds
0.95% Other Institutional Investors
94.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---